Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M893Revenue (TTM) $M627Net Margin (%)6.7Altman Z-Score1.7
Enterprise Value $M1,672EPS (TTM) $1.1Operating Margin %23.5Piotroski F-Score6
P/E(ttm)21.2Beneish M-Score-2.4Pre-tax Margin (%)10.1Higher ROA y-yY
Price/Book1.610-y EBITDA Growth Rate %--Quick Ratio1.9Cash flow > EarningsY
Price/Sales1.45-y EBITDA Growth Rate %59.5Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow11.9y-y EBITDA Growth Rate %95.0ROA % (ttm)2.5Higher Current Ratio y-yY
Dividend Yield %--PEG0.4ROE % (ttm)7.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M37.7ROIC % (ttm)7.4Gross Margin Increase y-yN

Gurus Latest Trades with LCI

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

LCI is held by these investors:

LCI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FARBER DAVID10% Owner 2017-11-08Sell10,000$25.03-5.31view
BEDROSIAN ARTHUR PCEO 2017-11-08Sell7,422$25.2-5.95view
BEDROSIAN ARTHUR PCEO 2017-02-06Buy10,000$2018.5view
FARBER DAVID10% Owner 2016-12-13Sell6,200$25.29-6.29view
FARBER DAVID10% Owner 2016-12-02Sell3,800$25-5.2view
Landis G. MichaelPrincipal Accounting Officer 2016-09-15Sell4,334$32.3-26.63view
Maher James M.Director 2016-09-01Sell1,478$33.91-30.11view
Landis G. MichaelPrincipal Accounting Officer 2016-08-31Sell6,786$33.41-29.06view
Ehlinger RobertVP and CIO 2016-06-23Sell37,141$25.06-5.43view
Ehlinger RobertVP and CIO 2016-06-20Sell62,859$25.4-6.69view

Quarterly/Annual Reports about LCI:

News about LCI:

Articles On GuruFocus.com
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of L Nov 09 2017 
Lannett To Present At The Jefferies 2017 London Healthcare Conference On November 15 Nov 09 2017 
Lannett Comments On Amended Civil Complaint Nov 01 2017 
New Research Coverage Highlights Annaly, Praxair, Tailored Brands, Lannett, Legg Mason, and AutoNati Oct 31 2017 
Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid® Oct 30 2017 
Lannett To Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call On Monday, Novem Oct 26 2017 
Lannett Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules USP, One Each For Full Oct 02 2017 
Lannett Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 5 mg/325 mg And 10 mg/325 Sep 27 2017 
Lannett Announces Dismissal Of Class Action Lawsuit Sep 26 2017 
Lannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg Sep 26 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat